Technical Analysis for INBX - Inhibrx, Inc.

Grade Last Price % Change Price Change
grade C 17.7547 2.33% 0.40
INBX closed down 4.3 percent on Monday, September 28, 2020, on 36 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical INBX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 2.33%
Hot IPO Pullback Bullish Swing Setup 2.33%
Outside Day Range Expansion 2.33%
20 DMA Support Bullish -2.07%
Narrow Range Bar Range Contraction -2.07%
Up 3 Days in a Row Strength -2.07%
20 DMA Support Bullish -0.87%
Crossed Above 20 DMA Bullish -0.48%
Narrow Range Bar Range Contraction 2.57%
NR7 Range Contraction 2.57%
Older End-of-Day Gignals for INBX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Resistance about 2 hours ago
10 DMA Resistance about 2 hours ago
Rose Above 10 DMA about 4 hours ago
Rose Above 20 DMA about 4 hours ago
Up 3% about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Biotechnology Health Pharmaceutical Industry Solid Tumors Clinical Trial Tumors Design Of Experiments Clinical Research Antitrypsin Deficiency Pseudomonas Pd L1 Sarcomas

Is INBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.9899
52 Week Low 15.76
Average Volume 99,123
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 17.70
10-Day Moving Average 17.63
Average True Range 1.46
ADX 10.35
+DI 17.51
-DI 13.54
Chandelier Exit (Long, 3 ATRs ) 16.80
Chandelier Exit (Short, 3 ATRs ) 20.15
Upper Bollinger Band 19.07
Lower Bollinger Band 16.33
Percent B (%b) 0.37
BandWidth 15.50
MACD Line -0.29
MACD Signal Line -0.29
MACD Histogram 0.0036
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.94
Resistance 3 (R3) 19.10 18.72 18.68
Resistance 2 (R2) 18.72 18.32 18.65 18.59
Resistance 1 (R1) 18.04 18.07 17.85 17.88 18.50
Pivot Point 17.66 17.66 17.57 17.59 17.66
Support 1 (S1) 16.98 17.26 16.79 16.82 16.20
Support 2 (S2) 16.60 17.01 16.53 16.11
Support 3 (S3) 15.92 16.60 16.03
Support 4 (S4) 15.76